Normax France investigational mRNA cancer vaccines will be manufactured for individuals based on the specific molecular features of their tumors which are called neoantigens. Training your immune system to recognize these neoantigen protein targets on the surface of your cancer cells could empower your body to control your cancer.

For more than a decade, cancer researchers have been developing a type of treatment known as a personalized cancer vaccine using various technologies, including mRNA and protein fragments, or peptides to target your neoantigens of your cancer. A personalized mRNA vaccine from Normax France could be a safe and effective tool for your doctors to use in the arsenal to fight your cancer.

Normax France plans to produce a personalized mRNA cancer vaccine for you, after tissue samples have been collected, within 1 to 2 months. Speed is especially important for individualized cancer vaccination. Ideally, a highly individualized vaccine combination to target your neoantigens should be designed and produced within 10 weeks of taking your tumor biopsy and blood sample.

Normax France is initiating clinical trial testing of personalized mRNA vaccines to target individual neoantigens. The goal is a complete and enduring response whereby all signs of the tumor disappear following treatment.

The manufacturing process starts with the identification of genetic mutations in a patient’s tumor cells that could give rise to neoantigens. Computer algorithms then predict which neoantigens are most likely to bind to receptors on T cells and stimulate an immune response.

The vaccine can include genetic sequences for many different neoantigens. The promise of personalized immunotherapy with mRNA vaccines is being able to activate T cells that will specifically recognize individual cancer cells based on their abnormal molecular features.